CRBN and plasma cell myeloma: Although the molecular mechanisms underlying the anti-myeloma activity of IMiDsR have been reported to involve the Cullin 4A (CUL4A)- Cereblon (CRBN) E3 ligase complex mediated proteasomal degradation of downstream targets (5).